Related Experiment Videos

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?

P Damier1, A Kastner, Y Agid

  • 1INSERM U289, Hôpital de la Salpêtrière, Paris, France.

Neurology
|May 1, 1996
PubMed

Insights

Monoamine oxidase B (MAO-B) in dopamine neurons does not increase Parkinson's disease (PD) vulnerability. However, MAO-B in glial cells may protect against oxidative stress from dopamine metabolism in PD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Hyperoxidation is implicated in Parkinson's disease (PD) neurodegeneration.
  • Oxidative degradation of dopamine by monoamine oxidase type B (MAO-B) produces free radicals, potentially contributing to PD pathology.

Purpose of the Study:

  • To investigate the distribution of MAO-B in the midbrain of PD patients and controls.
  • To determine if MAO-B presence in dopaminergic neurons correlates with their vulnerability in PD.

Main Methods:

  • Immunohistochemistry was used to detect MAO-B.
  • Double-labeling immunohistochemistry identified MAO-B in dopaminergic neurons.
  • MAO-B-positive glial cell density was quantified and correlated with neuronal loss.

Main Results:

  • MAO-B was found in glial cells, fibers, and neurons, including dopaminergic neurons, in both PD and control midbrains.
  • The loss of MAO-B-positive dopaminergic neurons was not greater than MAO-B-negative ones.
  • MAO-B-positive glial cell density was inversely correlated with neuronal loss in PD, being higher in less affected areas.

Conclusions:

  • MAO-B in dopamine neurons does not contribute to their vulnerability in Parkinson's disease.
  • MAO-B in glial cells may offer a protective effect against dopamine-induced oxidative stress.

Related Concept Videos